Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mochida: Profits Down Sharply due to Increase in Investment Costs
June 7, 2004
- REGULATORY NEWS IN BRIEF
June 7, 2004
- Zeria: Sales Down 1.2% to \54.3 Bil.
June 7, 2004
- PRESS SEMINR
June 7, 2004
- Ono: Consolidated Sales Rise \4.3 Bil. to \139 Bil.
May 31, 2004
- PRESS SEMINAR
May 31, 2004
- Tsumura: 4th Straight Year of Growth Marked
May 31, 2004
- OTC NEWS IN BRIEF
May 31, 2004
- Toyama Chemical: Sales Drop 49% Due to Transfer Ethical Drug Business to Taisho Toyama
May 31, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 31, 2004
- Kyowa Hakko Kogyo: Sales Up Virtually, Profits Jump
May 31, 2004
- WORLD NEWS IN BRIEF
May 31, 2004
- Cost Calculation Method Should Be Replaced with Free Price System: PhRMA President
May 31, 2004
- Top-12 TSE-Listed Makers Report 0.1% Decline in Sales
May 31, 2004
- BUSINESS NEWS IN BRIEF
May 31, 2004
- Meet the Leaders (31)
May 31, 2004
- BULLETIN
May 31, 2004
- Japanese Healthcare Q&A (8)
May 31, 2004
- Approval of Preventive Use of Tamiflu Recommended
May 31, 2004
- Annual Business Results
May 31, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…